Compare Microsoft (MSFT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Microsoft (MSFT) trades at $493.95, down 1.15% on the day, with a bullish technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.74 exceeding expectations of $4.24. Revenue growth is steady, reaching $281.72B in 2025, supported by a net income margin of 40.31% and a high ROE of 34.04%. News highlights AI leadership and Azure momentum, though capital expenditure concerns persist.

Outlook remains positive with an 80.49% analyst buy rating and a consensus price target of $560.43, implying significant upside. Risks include competitive pressures in AI, high valuation multiples like a P/E of 27.52, and macroeconomic volatility. The stock's strength in cloud computing and consistent profitability underpins long-term growth potential.

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.